
    
      This study is a multicenter epidemiology study at centers that are participating in GSK's
      pivotal Phase III candidate malaria vaccine 110021 ( NCT00866619) trial and will involve 4
      annual cross sectional surveys performed preferably at peak transmission.

      There will be no study vaccine administered in this epidemiology study.
    
  